EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Plasma biomarkers for afatinib monotherapy in EGFR-mutated non-small cell lung cancer: Novel insights from companion genomics analysis of the EXTRA study

Tomonori Makiguchi, Hisashi Tanaka, Kei Morikawa, Aya Hirata, Hidetoshi Itani, Shigeru Tanzawa, Kageaki Watanabe, Hiroyuki Yasuda, Kazuya Horiuchi, Hideyuki Nakagawa, Yoshitaka Seki, Yoshiro Nakahara und 19 weitere

Cancer Treatment and Research Communications · 2025 · 44 · 100952

DOI: 10.1016/j.ctarc.2025.100952 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2025. Verfasst von Tomonori Makiguchi und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Aomori, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Afatinib, Lung Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Boehringer Ingelheim, Boehringer Ingelheim Vetmedica Japan Co Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Plasma-based testing with circulating cell-free DNA (cfDNA) is an active area of biomarker exploratory studies in patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations. The Exosome-focused Translational Research for Afatinib study prospectively explored novel plasma biomarkers for afatinib monotherapy in patients with NSCLC harboring EGFR mutations using genomics, proteomics, epigenomics, and metabolomics. Herein, we present the results of the genomics part. MATERIALS AND METHODS: Clinical data of afatinib were matched with next generation sequencing (NGS)-based genomics data of cfDNA (n = 101) and extracellular vesicle DNA (evDNA) (n = 99) from pretreatment plasma samples. RESULTS: The detection sensitivity of cfDNA and evDNA mutations was 86 % (87/101) and 37 % (37/99), respectively. When cfDNA mutations were classified into tissue-matched (any EGFR mutations consistent with those identified in tissue) (n = 28), tissue-unmatched (n = 59), and mutation-undetected (n = 14) groups, cfDNA mutation status was a predictor of progression-free survival (PFS) (p 30 months and >80 %, respectively, with afatinib monotherapy. CONCLUSION: This is the first large-scale prospective study of NGS-based concurrent testing for plasma cfDNA and evDNA mutations. The findings suggest that cfDNA mutation status is a promising plasma biomarker for afatinib monotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungAfatinibLung NeoplasmsBiomarkers, TumorHumansFemaleMaleMiddle AgedErbB ReceptorsMutationAgedProspective StudiesCell-Free Nucleic AcidsGenomicsAdultHigh-Throughput Nucleotide SequencingAged, 80 and overProtein Kinase Inhibitors

Stichwörter der Autor:innen

AfatinibCell-free DNAExtracellular vesicle-derived DNANon-small cell lung cancerPlasma biomarker

Substanzen

AfatinibBiomarkers, TumorErbB ReceptorsEGFR protein, humanCell-Free Nucleic AcidsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Aomori, Japan.
  • Division of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan.
  • Department of Respiratory Medicine, Kyorin University School of Medicine, Tokyo, Japan.
  • Department of Respiratory Medicine, Japanese Red Cross Ise Hospital, Mie, Japan.
  • Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.
  • Department of Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.

Förderung

  • Boehringer Ingelheim
  • Boehringer Ingelheim Vetmedica Japan Co Ltd

Zitieren

APA

Makiguchi, T., Tanaka, H., Morikawa, K., Hirata, A., Itani, H., Tanzawa, S., Watanabe, K., Yasuda, H., Horiuchi, K., Nakagawa, H., Seki, Y., Nakahara, Y., Hayashi, K., Takahashi, N., Endo, T., Bessho, A., Okano, T., Takeyama, K., Kawase, A., …, & Seki, N. (2025). Plasma biomarkers for afatinib monotherapy in EGFR-mutated non-small cell lung cancer: Novel insights from companion genomics analysis of the EXTRA study. Cancer Treatment and Research Communications, 44, 100952. https://doi.org/10.1016/j.ctarc.2025.100952

Vancouver

Makiguchi T, Tanaka H, Morikawa K, Hirata A, Itani H, Tanzawa S, et al. Plasma biomarkers for afatinib monotherapy in EGFR-mutated non-small cell lung cancer: Novel insights from companion genomics analysis of the EXTRA study. Cancer Treatment and Research Communications. 2025;44:100952. doi:10.1016/j.ctarc.2025.100952

BibTeX
@article{Makiguchi2025,
  author = {Makiguchi, Tomonori and Tanaka, Hisashi and Morikawa, Kei and Hirata, Aya and Itani, Hidetoshi and Tanzawa, Shigeru and Watanabe, Kageaki and Yasuda, Hiroyuki and Horiuchi, Kazuya and Nakagawa, Hideyuki and Seki, Yoshitaka and Nakahara, Yoshiro and Hayashi, Kentaro and Takahashi, Nobumasa and Endo, Takeo and Bessho, Akihiro and Okano, Tetsuya and Takeyama, Kiyoshi and Kawase, Akikazu and Endo, Makoto and Maekura, Toshiya and Nemoto, Kenji and Takigawa, Nagio and Kishi, Kazuma and Soejima, Kenzo and Okuma, Yusuke and Togashi, Akira and Matsutani, Noriyuki and Shinchi, Hiroki and Ueda, Koji and Seki, Nobuhiko},
  title = {Plasma biomarkers for afatinib monotherapy in EGFR-mutated non-small cell lung cancer: Novel insights from companion genomics analysis of the EXTRA study},
  journal = {Cancer Treatment and Research Communications},
  year = {2025},
  volume = {44},
  pages = {100952},
  doi = {10.1016/j.ctarc.2025.100952}
}
Kostenlos starten →